@article{3088180,
    title = "Effect of parathyroidectomy versus risedronate on volumetric bone mineral density and bone geometry at the tibia in postmenopausal women with primary hyperparathyroidism",
    author = "Tournis, S. and Fakidari, E. and Dontas, I. and Liakou, C. and Antoniou, J. and Galanos, A. and Marketou, H. and Makris, K. and Katsalira, K. and Trovas, G. and Lyritis, G.P. and Papaioannou, N.",
    journal = "Journal of Bone and Mineral Metabolism",
    year = "2014",
    volume = "32",
    number = "2",
    pages = "151-158",
    publisher = "Springer Japan",
    issn = "0914-8779, 1435-5604",
    doi = "10.1007/s00774-013-0473-6",
    keywords = "alkaline phosphatase;  calcium;  osteocalcin;  parathyroid hormone;  phosphate;  risedronic acid;  vitamin D;  bone density conservation agent;  etidronic acid;  risedronic acid, adult;  aged;  article;  bone density;  bone geometry;  bone mineral;  calcium blood level;  Caucasian;  chemical analysis;  clinical article;  comparative study;  computer assisted tomography;  controlled study;  cortical bone;  dual energy X ray absorptiometry;  female;  femur neck;  follow up;  geometry;  human;  lumbar spine;  medical history;  medication compliance;  outcome assessment;  parathyroidectomy;  phosphate blood level;  physical examination;  postmenopause;  primary hyperparathyroidism;  priority journal;  tibia;  volumetric bone mineral density;  analogs and derivatives;  drug effects;  Hyperparathyroidism, Primary;  middle aged;  pathology;  postmenopause;  tibia, Bone Density;  Bone Density Conservation Agents;  Etidronic Acid;  European Continental Ancestry Group;  Female;  Humans;  Hyperparathyroidism, Primary;  Middle Aged;  Parathyroidectomy;  Postmenopause;  Tibia",
    abstract = "The objective of the study was to evaluate the effect of parathyroidectomy (PTX) versus 35 mg once-weekly (ow) risedronate administration on volumetric bone mineral density (vBMD) and bone geometry at the tibia in postmenopausal women with primary hyperparathyroidism (PHPT). Our open-label prospective observational study included 32 postmenopausal women with PHPT as the study group: 16 underwent PTX and 16 were treated with 35 mg ow risedronate for 2 years. We assessed areal BMD (aBMD) by DXA, and vBMD and bone mineral content (BMC) (cortical and trabecular area) by peripheral quantitative computed tomography (pQCT) at the tibia at baseline and at 2 years. Risedronate did not result in any significant change on vBMD and structural pQCT indices. PTX resulted in significant increase in trabecular (trab) BMC (6.44 %) and vBMD (4.64 %), with percent increase being significantly higher than risedronate (p < 0.05). At cortical sites, there was no significant change following PTX. However, the percent change in cortical (cort) vBMD was higher following PTX versus risedronate (0.39 % vs. -0.26 %, p < 0.05). In conclusion, in postmenopausal women with PHPT, PTX is superior to ow risedronate, in terms of improvement of trabecular mineralization and vBMD at the tibia, whereas the effect at cortical sites is less pronounced. © 2013 The Japanese Society for Bone and Mineral Research and Springer."
}